CG Oncology, Inc. (CGON)
(Delayed Data from NSDQ)
$26.31 USD
-0.38 (-1.42%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $26.51 +0.20 (0.76%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CGON 26.31 -0.38(-1.42%)
Will CGON be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CGON based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGON
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
Company News for May 14, 2025
CGON: What are Zacks experts saying now?
Zacks Private Portfolio Services
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for CGON
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 19th Options Now Available For CG Oncology (CGON)
CGON's Price Target Lowered by RBC Capital, Rating Maintained | CGON Stock News
RBC Capital Adjusts Price Target for CG Oncology (CGON) Amid Positive Outlook | CGON Stock News